Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Oxidative Stress
2017 Standout
Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
2014
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
2010
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation
2015 StandoutNobel
Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
2010
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes
2013 Standout
Radiotherapy for renal-cell carcinoma
2014
The translational landscape of mTOR signalling steers cancer initiation and metastasis
2012 Nature
Phase I Trial of Everolimus Plus Sorafenib for Patients with Advanced Renal Cell Cancer
2011
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Therapeutic cancer vaccines: are we there yet?
2010
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
AMPK: guardian of metabolism and mitochondrial homeostasis
2017 Standout
Hypomorphic Mutation in the Site-1 Protease Mbtps1 Endows Resistance to Persistent Viral Infection in a Cell-Specific Manner
2011 StandoutNobel
Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization
2016
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
New Insights into the Biology of Renal Cell Carcinoma
2011 StandoutNobel
mTOR signaling and drug development in cancer
2010
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
2021 Standout
EMT Transition States during Tumor Progression and Metastasis
2018 Standout
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
A Review on the Dietary Flavonoid Kaempferol
2011 Standout
mTOR at the nexus of nutrition, growth, ageing and disease
2020 Standout
The evolving role of dendritic cells in cancer therapy
2010
Lung cancer: current therapies and new targeted treatments
2016 Standout
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
mTOR Signaling in Growth, Metabolism, and Disease
2017 Standout
Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain
2017 StandoutNobel
Going viral with cancer immunotherapy
2014
Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy
2016
On the Dependency of Cellular Protein Levels on mRNA Abundance
2016 Standout
Detection of Rapalog-Mediated Therapeutic Response in Renal Cancer Xenografts Using 64Cu-bevacizumab ImmunoPET
2013
Quality of life in patients with metastatic renal cell carcinoma: The importance of patient-reported outcomes
2009
The VHL/HIF axis in clear cell renal carcinoma
2012 StandoutNobel
The emerging role of MET/HGF inhibitors in oncology
2013
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Radiation-Associated Kidney Injury
2010
Regulation of type I interferon responses
2013 Standout
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
New cancer targets emerging from studies of the Von Hippel‐Lindau tumor suppressor protein
2010 StandoutNobel
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
The PI3K Pathway in Human Disease
2017 Standout
ROS and the DNA damage response in cancer
2018 Standout
Renal cell carcinoma
2017 Standout
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
2015
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
2015
Superoxide Dismutase Mimics: Chemistry, Pharmacology, and Therapeutic Potential
2010
A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis
2014
Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
2009
Management of glioblastoma: State of the art and future directions
2020 Standout
Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and Applications
2019 Standout
eIF3d is an mRNA cap-binding protein that is required for specialized translation initiation
2016 StandoutNatureNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context
2012 Standout
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
MET As a Possible Target for Non–Small-Cell Lung Cancer
2013
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
2017 Standout
Reactive species in non-equilibrium atmospheric-pressure plasmas: Generation, transport, and biological effects
2016 Standout
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009 Standout
HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation
2015
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
2014 Standout
Targeted therapy for advanced renal cell carcinoma
2008
Works of J. Jac being referenced
Vaccination of Prostate Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax)
2008
Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer
2008
The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT)
2007
A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
2009
Motexafin Gadolinium for the Treatment of Metastatic Renal Cell Carcinoma: Phase II Study Results
2008
Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α)
2009
A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
2007
Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.
2011
Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial
2008
Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.
2011
A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC)
2007
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
2018
A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC)
2008
Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.
2010